Baseline characteristics
| . | CNS HL cohort, n (%) . | COG AHOD1331, n (%) . | EuroNet-PHL-C1 (excluding France and Austria),∗ n (%) . |
|---|---|---|---|
| Sex | |||
| Female | 13 (28.9) | 276 (47) | 716 (47) |
| Male | 32 (71.1) | 311 (53) | 812 (53) |
| Age | <10 y: 9 (20.0) | <12 y: 90 (15.3) | <13 y: 472 (31) |
| 10-18 y: 35 (77.8) | 12-21 y: 497 (84.7) | ≥13 y: 1056 (69) | |
| >18 y: 1 (2.2) | |||
| Ann Arbor stage | |||
| IA | 28 (1.8) | ||
| IB | 5 (0.3) | ||
| IIA | 514 (33.6) | ||
| IIAE | 66 (4.3) | ||
| IIB | 149 (9.8) | ||
| IIBE | 121 (20.6) | 88 (5.6) | |
| IIIA | 2 (4.4) | 130 (8.5) | |
| IIIAE | 17 (1.1) | ||
| IIIB | 1 (2.2) | 111 (7.3) | |
| IIIBE | 2 (4.4) | 113 (19.3) | 35 (2.3) |
| IVA | 12 (26.7) | 128 (8.4) | |
| IVAE | 7 (15.6) | 167 (28.4) | 41 (2.7) |
| IVB | 9 (20.0) | 186 (31.7) | 126 (8.2) |
| IVBE | 12 (26.7) | 90 (5.9) | |
| Histology | |||
| Nodular sclerosing | 31 (68.9) | 449 (76.5) | 1063 (69.6) |
| Mixed cellularity | 5 (11.1) | 33 (5.6) | 305 (20) |
| Lymphocyte rich | 1 (2.2) | 7 (1.2) | 32 (2.1) |
| Lymphocyte depleted | 6 (0.4) | ||
| Lymphocyte predominant | |||
| HL, not otherwise specified | 3 (6.7) | 98 (16.7) | 81 (5.3) |
| Gray zone lymphoma | 5 (0.3) | ||
| Information not available | 5 (11.1) | 36 (2.3) | |
| Trial | |||
| AHOD1331 | 20 (44.4) | ||
| EuroNet-PHL-C1 | 9 (20) | ||
| EuroNet-PHL-C2 | 16 (35.6) | ||
| Number of CNS lesions per patient | |||
| 1 | 37 (82.2) | ||
| 2 | 6 (13.3) | ||
| 3 | 2 (4.4) | ||
| Location | |||
| Skull | 2 (3.6) | ||
| Cervical spine | 3 (5.5) | ||
| Thoracic spine | 25 (45.5) | ||
| Lumbar spine | 12 (21.8) | ||
| Sacrum | 13 (23.6) | ||
| Origin of the CNS mass | |||
| CNS | |||
| Skeletal | 25 (45.5) | ||
| Muscle/soft tissue (including lymph node) | 22 (40.0) | ||
| Origin unclear | 8 (14.5) | ||
| Intensity of FDG uptake of CNS lesions at initial staging (according to Deauville scoring system) | |||
| 3 | 2 (3.6) | ||
| 4 | 5 (9.1) | ||
| 5 | 47 (85.5) | ||
| Information not available | 1 (1.8) |
| . | CNS HL cohort, n (%) . | COG AHOD1331, n (%) . | EuroNet-PHL-C1 (excluding France and Austria),∗ n (%) . |
|---|---|---|---|
| Sex | |||
| Female | 13 (28.9) | 276 (47) | 716 (47) |
| Male | 32 (71.1) | 311 (53) | 812 (53) |
| Age | <10 y: 9 (20.0) | <12 y: 90 (15.3) | <13 y: 472 (31) |
| 10-18 y: 35 (77.8) | 12-21 y: 497 (84.7) | ≥13 y: 1056 (69) | |
| >18 y: 1 (2.2) | |||
| Ann Arbor stage | |||
| IA | 28 (1.8) | ||
| IB | 5 (0.3) | ||
| IIA | 514 (33.6) | ||
| IIAE | 66 (4.3) | ||
| IIB | 149 (9.8) | ||
| IIBE | 121 (20.6) | 88 (5.6) | |
| IIIA | 2 (4.4) | 130 (8.5) | |
| IIIAE | 17 (1.1) | ||
| IIIB | 1 (2.2) | 111 (7.3) | |
| IIIBE | 2 (4.4) | 113 (19.3) | 35 (2.3) |
| IVA | 12 (26.7) | 128 (8.4) | |
| IVAE | 7 (15.6) | 167 (28.4) | 41 (2.7) |
| IVB | 9 (20.0) | 186 (31.7) | 126 (8.2) |
| IVBE | 12 (26.7) | 90 (5.9) | |
| Histology | |||
| Nodular sclerosing | 31 (68.9) | 449 (76.5) | 1063 (69.6) |
| Mixed cellularity | 5 (11.1) | 33 (5.6) | 305 (20) |
| Lymphocyte rich | 1 (2.2) | 7 (1.2) | 32 (2.1) |
| Lymphocyte depleted | 6 (0.4) | ||
| Lymphocyte predominant | |||
| HL, not otherwise specified | 3 (6.7) | 98 (16.7) | 81 (5.3) |
| Gray zone lymphoma | 5 (0.3) | ||
| Information not available | 5 (11.1) | 36 (2.3) | |
| Trial | |||
| AHOD1331 | 20 (44.4) | ||
| EuroNet-PHL-C1 | 9 (20) | ||
| EuroNet-PHL-C2 | 16 (35.6) | ||
| Number of CNS lesions per patient | |||
| 1 | 37 (82.2) | ||
| 2 | 6 (13.3) | ||
| 3 | 2 (4.4) | ||
| Location | |||
| Skull | 2 (3.6) | ||
| Cervical spine | 3 (5.5) | ||
| Thoracic spine | 25 (45.5) | ||
| Lumbar spine | 12 (21.8) | ||
| Sacrum | 13 (23.6) | ||
| Origin of the CNS mass | |||
| CNS | |||
| Skeletal | 25 (45.5) | ||
| Muscle/soft tissue (including lymph node) | 22 (40.0) | ||
| Origin unclear | 8 (14.5) | ||
| Intensity of FDG uptake of CNS lesions at initial staging (according to Deauville scoring system) | |||
| 3 | 2 (3.6) | ||
| 4 | 5 (9.1) | ||
| 5 | 47 (85.5) | ||
| Information not available | 1 (1.8) |
EuroNet-PHL-C2 primary results have not yet been published; therefore, patient details from that trial are not included here.